Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 1
2012 1
2015 2
2016 2
2017 2
2020 4
2022 1
2023 2
2024 3
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry.
Giacomelli A, Capra N, Lolatto R, Gagliardini R, Clemente T, Calza L, Torti C, Lagi F, Fornabaio C, Marchetti G, Orofino G, Spagnuolo V; for PRESTIGIO Study Group. Giacomelli A, et al. Among authors: fornabaio c. Clin Infect Dis. 2025 Dec 24;81(5):e370-e374. doi: 10.1093/cid/ciaf421. Clin Infect Dis. 2025. PMID: 40749106 Free PMC article.
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era.
Papaioannu Borjesson R, Diotallevi S, Lolatto R, Cenderello G, Comi L, Cascio A, Saracino A, Clemente T, Mazzitelli M, Lo Caputo S, Armenia D, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Papaioannu Borjesson R, et al. J Antimicrob Chemother. 2025 Sep 3;80(9):2369-2374. doi: 10.1093/jac/dkaf211. J Antimicrob Chemother. 2025. PMID: 40693490
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry.
Armenia D, Marchegiani G, Spagnuolo V, Bellocchi MC, Galli L, Clemente T, Carioti L, Lolatto R, Ferrara M, Gagliardini R, Marchetti GC, Torti C, De Socio G, Fornabaio C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2025 Nov 4;80(11):3101-3106. doi: 10.1093/jac/dkaf349. J Antimicrob Chemother. 2025. PMID: 40990139 Free PMC article.
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry.
Clemente T, Diotallevi S, Minisci D, Di Biagio A, Lolatto R, Attala L, Cenderello G, Siribelli A, Muccini C, Lo Caputo S, Tavio M, Papaioannu Borjesson R, Giacomelli A, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):731-737. doi: 10.1093/jac/dkae465. J Antimicrob Chemother. 2025. PMID: 39727173
Lower aids-related hospitalizations in women living with HIV multidrug resistance.
Papaioannu Borjesson R, Galli L, Lolatto R, Menzaghi B, Feasi M, Gulminetti R, Fornabaio C, Cattelan AM, Bonora S, Lagi F, Zazzi M, Castagna A, Spagnuolo V; on behalf of PRESTIGIO Study Group. Papaioannu Borjesson R, et al. Among authors: fornabaio c. AIDS. 2024 Mar 1;38(3):435-438. doi: 10.1097/QAD.0000000000003781. Epub 2024 Feb 1. AIDS. 2024. PMID: 38300163 No abstract available.
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).
Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G. Torti C, et al. Among authors: fornabaio c. Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. Int J Epidemiol. 2017. PMID: 26445966 No abstract available.
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. Among authors: fornabaio c. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
27 results